KDR and cancer: Since in the recent years various Src inhibitors were used for therapeutic purposes in cancer and anti-angiogenesis treatments [25], we tested the effect of Src-specific inhibitor, SU6656 to inhibit phosphorylation of VEGFR-2 at Y1173.